Navigation Links
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Date:2/14/2008

y will streamline operations by reducing its work force. In addition, Neil Kurtz, M.D., the company's President and Chief Executive Officer, will assume oversight of all clinical development programs. Michael Murphy, who has served as Chief Medical Officer, will leave the company at the end of the month to pursue other interests.

"Our 2008 strategic plan builds on the clinical successes of our lead compounds and our on-going genetics collaboration with Eisai while enabling us to be opportunistic and fiscally prudent," said Dr. Kurtz. "Our goal is to exploit the versatility of our product candidates by moving them forward strategically through at least proof-of-concept, while being aggressive in our pursuit of corporate partnerships."

Conference Call/Webcast Information

TorreyPines Therapeutics will host a conference call and Webcast at 11 a.m. EST today. The audio Webcast can be accessed at http://www.torreypinestherapeutics.com. To participate in this call, dial 785-830-7975 and enter the passcode 1575547. For a limited period following the call, a replay will be available beginning at 2 p.m. EST. The replay can be accessed by calling 719-457-0820 and entering passcode 1575547.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small molecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at http://www.torreypinestherapeutics.com

This press release contains forward-looking statements or predictions, including statements regarding the company's
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
5. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
8. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
9. ImaRx Therapeutics Transitions Business Strategy
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 2015 Future Market Insights (FMI) ... Glucose Monitoring Systems Market: Global Industry Analysis and Opportunity ... global continuous glucose monitoring systems market was valued at ... reach US$ 788.4 Mn by 2020, registering a CAGR ... Global continuous glucose monitoring systems market is ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... of Defense Continues Study of Copper as Effective ... Improving Indoor Air Quality, NEW YORK, Nov. ... determining the,antimicrobial effectiveness of copper, brass and bronze ... CDA President Andrew G.,Kireta Sr. Of the ...
... To Enroll 4,000 Patients Worldwide, MENLO PARK, ... it is launching a global Phase III clinical ... novel combination therapy CGT-2168.,The program, which includes the ... at hundreds of sites in the United States, ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... 2015 , ... “Engage: Don’t Just Age” will be the ... symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort Casino in ... executives, administrators, directors of nursing, rehabilitation managers and other management and corporate personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), ... we treat aging diseases. , BioViva announces it has begun a fundraiser through ... Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... Feb. 3 When Americans are asked about the ... Poll, commissioned by the,National Court Appointed Special Advocate (CASA) ... nothing about the experiences of children in,foster care, and ... these,children. When adults do think of children in ...
... and PACS Industry Veteran , Shawn Gibbons ... Compressus, Inc., leaders in healthcare IT systems interoperability ... of Janine Broda to chief marketing officer and ... president and general manager of the MEDxConnect(TM) division.Proven ...
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... and distributor of high-quality,pharmaceutical grade glucose products ... invited to make a corporate presentation at ... Conference. , This ...
... are found to slow damage , , TUESDAY, Feb. 3 ... loss caused by Alzheimer,s disease, a new study says. ... University found that insulin acts as a shield that deflects ... responsible for forming memories. , "Therapeutics designed to ...
... Mich., Feb. 3 Perrigo Company,(Nasdaq: PRGO ; TASE) today announced results for its fiscal year 2009 second,quarter and six months that ended December 27, 2008. ... Perrigo Company, (in ... Second Quarter Six Months, ... 2009 2008 2009 ...
... MOUNTAIN VIEW, Calif., Feb. 3 MAP Pharmaceuticals, ... that the waiting period under the Hart-Scott-Rodino Act ... with AstraZeneca has expired, and the agreement is ... AstraZeneca will jointly develop and commercialize UDB, MAP ...
Cached Medicine News:Health News:National CASA Association Aims to Eliminate the Foster Care Stigma 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 2Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 3Health News:Insulin May Protect Against Alzheimer's 2Health News:Perrigo Reports Record Second Quarter Sales 2Health News:Perrigo Reports Record Second Quarter Sales 3Health News:Perrigo Reports Record Second Quarter Sales 4Health News:Perrigo Reports Record Second Quarter Sales 5Health News:Perrigo Reports Record Second Quarter Sales 6Health News:Perrigo Reports Record Second Quarter Sales 7Health News:Perrigo Reports Record Second Quarter Sales 8Health News:Perrigo Reports Record Second Quarter Sales 9Health News:Perrigo Reports Record Second Quarter Sales 10Health News:Perrigo Reports Record Second Quarter Sales 11Health News:Perrigo Reports Record Second Quarter Sales 12Health News:Perrigo Reports Record Second Quarter Sales 13Health News:Perrigo Reports Record Second Quarter Sales 14Health News:Perrigo Reports Record Second Quarter Sales 15Health News:Perrigo Reports Record Second Quarter Sales 16Health News:Perrigo Reports Record Second Quarter Sales 17Health News:Perrigo Reports Record Second Quarter Sales 18Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 2Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 3Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 4
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter features a female luer on the single leg. A rigid "Y" has two legs with white clamps and terminate with male luers....
Medicine Products: